• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium.微生理系统评估:TEX-VAL 组织芯片测试联盟的经验。
Toxicol Sci. 2022 Jul 28;188(2):143-152. doi: 10.1093/toxsci/kfac061.
2
Opportunities and challenges in the wider adoption of liver and interconnected microphysiological systems.更广泛采用肝脏及相互连接的微生理系统所面临的机遇与挑战。
Exp Biol Med (Maywood). 2017 Oct;242(16):1593-1604. doi: 10.1177/1535370217708976. Epub 2017 May 15.
3
Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development.微生理系统:药物开发中采用的利益相关者的挑战。
Cells Tissues Organs. 2022;211(3):269-281. doi: 10.1159/000517422. Epub 2021 Aug 11.
4
Fitting tissue chips and microphysiological systems into the grand scheme of medicine, biology, pharmacology, and toxicology.将组织芯片和微生理系统融入医学、生物学、药理学和毒理学的整体框架之中。
Exp Biol Med (Maywood). 2017 Oct;242(16):1559-1572. doi: 10.1177/1535370217732765.
5
Microphysiological Systems: Design, Fabrication, and Applications.微生理系统:设计、制造与应用
ACS Biomater Sci Eng. 2020 Jun 8;6(6):3231-3257. doi: 10.1021/acsbiomaterials.9b01667. Epub 2020 May 10.
6
Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective.从研发到推广的组织芯片之旅:制药行业视角
Exp Biol Med (Maywood). 2017 Oct;242(16):1579-1585. doi: 10.1177/1535370217715441. Epub 2017 Jun 16.
7
Microphysiological Systems (Tissue Chips) and their Utility for Rare Disease Research.微生理系统(组织芯片)及其在罕见病研究中的应用。
Adv Exp Med Biol. 2017;1031:405-415. doi: 10.1007/978-3-319-67144-4_23.
8
Microphysiological systems in early stage drug development: Perspectives on current applications and future impact.微生理系统在药物早期开发中的应用:当前应用及未来影响的展望。
J Toxicol Sci. 2021;46(3):99-114. doi: 10.2131/jts.46.99.
9
Facilitating the commercialization and use of organ platforms generated by the microphysiological systems (Tissue Chip) program through public-private partnerships.通过公私合作促进微生理系统(组织芯片)项目所产生的器官平台的商业化及应用。
Comput Struct Biotechnol J. 2016 May 10;14:207-210. doi: 10.1016/j.csbj.2016.04.003. eCollection 2016.
10
Bioethical implications of organ-on-a-chip on modernizing drug development.器官芯片对药物开发现代化的生物伦理影响。
Artif Organs. 2023 Oct;47(10):1553-1558. doi: 10.1111/aor.14620. Epub 2023 Aug 14.

引用本文的文献

1
Human Small Intestinal Tissue Models to Assess Barrier Permeability: Comparative Analysis of Caco-2 Cells, Jejunal and Duodenal Enteroid-Derived Cells, and EpiIntestinal Tissues in Membrane-Based Cultures with and Without Flow.用于评估屏障通透性的人小肠组织模型:基于膜的培养中Caco-2细胞、空肠和十二指肠肠上皮衍生细胞以及EpiIntestinal组织在有无流动情况下的比较分析。
Bioengineering (Basel). 2025 Jul 28;12(8):809. doi: 10.3390/bioengineering12080809.
2
hTERT and SV40LgT Renal Cell Lines Adjust Their Transcriptional Responses After Copy Number Changes from the Parent Proximal Tubule Cells.hTERT和SV40LgT肾细胞系在与亲代近端小管细胞相比拷贝数发生变化后,调整其转录反应。
Int J Mol Sci. 2025 Apr 11;26(8):3607. doi: 10.3390/ijms26083607.
3
Application of new approach methodologies for nonclinical safety assessment of drug candidates.新方法学在候选药物非临床安全性评估中的应用。
Nat Rev Drug Discov. 2025 May 2. doi: 10.1038/s41573-025-01182-9.
4
Comparative Analysis of Proximal Tubule Cell Sources for In Vitro Studies of Renal Proximal Tubule Toxicity.用于肾近端小管毒性体外研究的近端小管细胞来源的比较分析
Biomedicines. 2025 Feb 24;13(3):563. doi: 10.3390/biomedicines13030563.
5
Comparative analysis of Caco-2 cells and human jejunal and duodenal enteroid-derived cells in gel- and membrane-based barrier models of intestinal permeability.在基于凝胶和膜的肠道通透性屏障模型中对Caco-2细胞与源自人空肠和十二指肠的肠上皮细胞进行比较分析。
Toxicol Sci. 2025 Apr 1;204(2):181-197. doi: 10.1093/toxsci/kfaf011.
6
Comparative analysis of the physiological and transport functions of various sources of renal proximal tubule cells under static and fluidic conditions in PhysioMimix T12 platform.在PhysioMimix T12平台上,对静态和流体条件下各种来源的肾近端小管细胞的生理和转运功能进行比较分析。
Drug Metab Dispos. 2025 Jan;53(1):100001. doi: 10.1124/dmd.124.001488. Epub 2024 Nov 22.
7
Intestinal organ chips for disease modelling and personalized medicine.肠道器官芯片用于疾病建模和个性化医学。
Nat Rev Gastroenterol Hepatol. 2024 Nov;21(11):751-773. doi: 10.1038/s41575-024-00968-3. Epub 2024 Aug 27.
8
Liver-on-chips for drug discovery and development.用于药物发现与开发的芯片肝脏模型
Mater Today Bio. 2024 Jul 2;27:101143. doi: 10.1016/j.mtbio.2024.101143. eCollection 2024 Aug.
9
Challenges and Future Perspectives in Modeling Neurodegenerative Diseases Using Organ-on-a-Chip Technology.利用类器官芯片技术建模神经退行性疾病的挑战和未来展望。
Adv Sci (Weinh). 2024 Aug;11(32):e2403892. doi: 10.1002/advs.202403892. Epub 2024 Jun 23.
10
Recommendations on fit-for-purpose criteria to establish quality management for microphysiological systems and for monitoring their reproducibility.关于建立微生理系统质量管理和监测其重现性的适用标准的建议。
Stem Cell Reports. 2024 May 14;19(5):604-617. doi: 10.1016/j.stemcr.2024.03.009. Epub 2024 Apr 25.

本文引用的文献

1
A Model of Human Small Airway on a Chip for Studies of Subacute Effects of Inhalation Toxicants.用于吸入性毒性物质亚急性效应研究的人小气道芯片模型。
Toxicol Sci. 2022 May 26;187(2):267-278. doi: 10.1093/toxsci/kfac036.
2
Research and Development of Microphysiological Systems in Japan Supported by the AMED-MPS Project.由日本医疗研究开发机构微生理系统项目支持的日本微生理系统研发
Front Toxicol. 2021 Apr 29;3:657765. doi: 10.3389/ftox.2021.657765. eCollection 2021.
3
Update and Evaluation of a High-Throughput In Vitro Mass Balance Distribution Model: IV-MBM EQP v2.0.高通量体外质量平衡分布模型的更新与评估:IV-MBM EQP v2.0
Toxics. 2021 Nov 20;9(11):315. doi: 10.3390/toxics9110315.
4
Emerging technologies and their impact on regulatory science.新兴技术及其对监管科学的影响。
Exp Biol Med (Maywood). 2022 Jan;247(1):1-75. doi: 10.1177/15353702211052280. Epub 2021 Nov 16.
5
The Future of Uncertainty Factors With In Vitro Studies Using Human Cells.人类细胞体外研究中不确定性因素的未来。
Toxicol Sci. 2022 Feb 28;186(1):12-17. doi: 10.1093/toxsci/kfab134.
6
Adoption of organ-on-chip platforms by the pharmaceutical industry.制药行业对芯片器官平台的采用。
Nat Rev Drug Discov. 2021 Dec;20(12):961-962. doi: 10.1038/s41573-021-00323-0.
7
Prediction of hepatic drug clearance with a human microfluidic four-cell liver acinus microphysiology system.应用人微流控四细胞肝小叶微生理系统预测肝脏药物清除率。
Toxicology. 2021 Nov;463:152954. doi: 10.1016/j.tox.2021.152954. Epub 2021 Sep 17.
8
Human microphysiological systems for drug development.用于药物研发的人体微生理系统。
Science. 2021 Sep 17;373(6561):1304-1306. doi: 10.1126/science.abc3734. Epub 2021 Sep 16.
9
Putting Science into Standards workshop on standards for organ-on-chip.将科学纳入标准——器官芯片标准研讨会。
Stem Cell Reports. 2021 Sep 14;16(9):2076-2077. doi: 10.1016/j.stemcr.2021.07.010.
10
Applicability of organ-on-chip systems in toxicology and pharmacology.器官芯片系统在毒理学和药理学中的适用性。
Crit Rev Toxicol. 2021 Jul;51(6):540-554. doi: 10.1080/10408444.2021.1953439. Epub 2021 Aug 31.

微生理系统评估:TEX-VAL 组织芯片测试联盟的经验。

Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium.

机构信息

Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas 77843, USA.

Institute of Biosciences and Technology, Texas A&M University, Houston, Texas 77030, USA.

出版信息

Toxicol Sci. 2022 Jul 28;188(2):143-152. doi: 10.1093/toxsci/kfac061.

DOI:10.1093/toxsci/kfac061
PMID:35689632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9333404/
Abstract

Much has been written and said about the promise and excitement of microphysiological systems, miniature devices that aim to recreate aspects of human physiology on a chip. The rapid explosion of the offerings and persistent publicity placed high expectations on both product manufacturers and regulatory agencies to adopt the data. Inevitably, discussions of where this technology fits in chemical testing paradigms are ongoing. Some end-users became early adopters, whereas others have taken a more cautious approach because of the high cost and uncertainties of their utility. Here, we detail the experience of a public-private collaboration established for testing of diverse microphysiological systems. Collectively, we present a number of considerations on practical aspects of using microphysiological systems in the context of their applications in decision-making. Specifically, future end-users need to be prepared for extensive on-site optimization and have access to a wide range of imaging and other equipment. We reason that cells, related reagents, and the technical skills of the research staff, not the devices themselves, are the most critical determinants of success. Extrapolation from concentration-response effects in microphysiological systems to human blood or oral exposures, difficulties with replicating the whole organ, and long-term functionality remain as critical challenges. Overall, we conclude that it is unlikely that a rodent- or human-equivalent model is achievable through a finite number of microphysiological systems in the near future; therefore, building consensus and promoting the gradual incorporation of these models into tiered approaches for safety assessment and decision-making is the sensible path to wide adoption.

摘要

人们已经撰写和讨论了很多关于微生理系统的前景和兴奋点,这是一种旨在在芯片上重现人体生理功能的微型设备。微生理系统的产品供应迅速增加,宣传持续不断,这使得产品制造商和监管机构都对采用这些数据寄予厚望。不可避免的是,关于这项技术如何适应化学测试模式的讨论仍在继续。一些终端用户成为了早期采用者,而另一些用户则采取了更为谨慎的方法,因为其成本高且使用效果不确定。在这里,我们详细介绍了一个公私合作的经验,该合作是为了测试各种微生理系统而建立的。我们共同提出了一些关于在微生理系统的应用背景下,在决策过程中使用微生理系统的实际方面的考虑因素。具体来说,未来的终端用户需要为广泛的现场优化做好准备,并能够获得广泛的成像和其他设备。我们认为,细胞、相关试剂以及研究人员的技术技能,而不是设备本身,是成功的最关键决定因素。从微生理系统的浓度-反应效应推断到人体血液或口服暴露,复制整个器官的困难以及长期功能仍然是关键挑战。总的来说,我们得出的结论是,在不久的将来,通过有限数量的微生理系统实现啮齿动物或人类等效模型的可能性不大;因此,建立共识并促进这些模型逐渐纳入分层方法,用于安全性评估和决策,是广泛采用的明智途径。